Science on Campus

The institutions on the Buch campus collaborate closely and integrate basic and patientoriented research in a unique way. The results of this multifaceted collaboration are leading to better prevention, diagnosis and treatment of diseases – increasingly also with marketable procedures and products. The impact of the research location Berlin-Buch on the economic development and the job market situation in Berlin as a whole is increasing.

Research has an impact!

How can processes in the body and the development of diseases be explained on the molecular level? Which drugs can specifically target and intervene in the biochemistry and physiology of the body? Research activities at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Germany’s only non-university research institute for molecular pharmacology, are concerned with these questions. FMP employees conduct basic research with the goal of identifying new bioactive molecules and characterizing their interaction with their biological targets in cells or organisms. These molecules serve as tools in basic biomedical research and can be further developed for the treatment, prevention or diagnosis of disease. For this purpose, researchers from the fields of chemistry, biology, biochemistry, pharmacology, physics and medicine work closely together to optimize the medicine of the future.

The FMP provides state-of-the-art technologies for this purpose: For example, facilities for NMR spectroscopy for the structure elucidation of biomolecules are located in three separate buildings. To efficiently search for new drugs, high-performance robots in the screening unit test huge substance libraries for their physiological effects. The FMP remains as initiator and continues to be associated with EU-OPENSCREEN as a partner institute. A total of approximately 300 employees and guest researchers work at the FMP. The budget for 2018 totaled 28.9 million euros, including 8.2 million third-party funds. The FMP is a member of the Leibniz Association.